Compare BRX & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRX | KRYS |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 7.8B |
| IPO Year | 2013 | 2017 |
| Metric | BRX | KRYS |
|---|---|---|
| Price | $29.98 | $254.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | $30.42 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 3.1M | 262.2K |
| Earning Date | 05-11-2026 | 05-18-2026 |
| Dividend Yield | ★ 4.07% | N/A |
| EPS Growth | 12.61 | ★ 128.00 |
| EPS | 1.25 | ★ 6.84 |
| Revenue | ★ $1,371,597,000.00 | $389,130,000.00 |
| Revenue This Year | $5.13 | $40.88 |
| Revenue Next Year | $1.18 | $35.16 |
| P/E Ratio | ★ $24.19 | $37.92 |
| Revenue Growth | 6.73 | ★ 33.94 |
| 52 Week Low | $23.84 | $123.03 |
| 52 Week High | $30.71 | $298.30 |
| Indicator | BRX | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 63.66 | 40.80 |
| Support Level | $25.49 | $233.64 |
| Resistance Level | N/A | $293.60 |
| Average True Range (ATR) | 0.47 | 12.46 |
| MACD | -0.05 | -2.29 |
| Stochastic Oscillator | 57.10 | 6.26 |
Brixmor Property Group Inc is a real estate investment trust based in the United States. The company owns and operates a portfolio of grocery-anchored community and neighborhood shopping centers across the United States. It leases its rentable areas to retailers, restaurants, theatres, entertainment venues, and fitness centers, with the company's tenants consisting of large department stores, discount retailers, and grocery stores. The company is an internally managed REIT. The company operates in Florida, Texas, California, New York, Pennsylvania, Illinois, New Jersey, Georgia, North Carolina, Michigan, Ohio and other states.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.